Selective serotonin reuptake inhibitors in the treatment of affective disorders - III. Tolerability, safety and pharmacoeconomics

Journal of Psychopharmacology

Volumn 12, Issue 3 SUPPL. B, 1998, Pages

  Goldstein, Burton J ^a   Goodnick, Paul J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Agitation; Cognitive impairment; Cost effectiveness; Discontinuation reaction; Fatigue; Insomnia; Sexual dysfunction; Weight gain

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ABDOMINAL PAIN; AFFECTIVE NEUROSIS; AGITATION; AKATHISIA; ANTICHOLINERGIC EFFECT; BODY WEIGHT; CLINICAL TRIAL; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CHOICE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MANIA; META ANALYSIS; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SKIN DEFECT; SLEEP DISORDER; SOMNOLENCE; TREMOR; VERTIGO; XEROSTOMIA;

EID: 0031732861     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881198012003041     Document Type: Review

References (372)

1. Achamallah NS, Decker DH (1991) Mania induced by fluoxetine in an adolescent patient [letter]. Am J Psychiatry 148: 1404.
2. Achamallah NS (1992) Visual hallucinations after combining fluoxetine and dextromethorphan. Am J Psychiatry 149: 1406.
3. Adverse Drug Reactions Advisory Committee (ADRAC) (1996) SSRIs and withdrawal syndrome. Austr Adverse Drug Reactions Bull 15: 3.
4. Agren H, Aberg-Wistedt A, Akerblad A-C (1998) Sertraline vs. paroxetine in major depression - a multicenter, double-blind, 24-week comparison. New Research Abstracts American Psychiatric Association Annual Meeting, Toronto.
5. Aguglia E, Casacchia M, Cassano GB, Faravelli C, Ferrari G, Giordano P, Pancheri P, Ravizza L, Trabucchi M, Bolino F (1993) Double-blind study of the efficacy and safety of sertraline vs. fluoxetine in major depression. Int Clin Psychopharmacol 8: 197-202.
6. Akiskal HS, Walker P, Puzantian UR (1983) Bipolar outcome in the course of depressive illness. J Affect Disord 51: 15-28.
7. Alderman J, Wolkow, R., Chung M, Johnston H (1998) Sertraline treatment of children and adolescents with obsessive compulsive disorder or depression: Pharmacokinetics, tolerability and efficacy. J Am Acad Child Adolesc Psychiatry 37: 386-394.
8. Allard P, Marcusson JO, Ross SB (1994) (3H)GBR-12935 binding to cytochrome P450 in the human brain. J Neurochem 62: 342-348.
9. Allen D, Lader M, Curran HV (1988) A comparative study of the interactions of alcohol with amitriptyline, fluoxetine, and placebo in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 12: 63-80.
10. Allen D, Lader M (1989) Interactions of alcohol with amitriptyline, fluoxetine and placebo in normal subjects. Int Clin Psychopharmacol 4 (Suppl. 1): 7-14.
11. Amado-Boccara I, Gougoulis N, Poirier-Littre MF, Galinowski A, Loo H (1994) Effects of antidepressants on cognitive functions. Review of the literature. Encéphale 20: 65-77.
12. Ames D (1993) Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome - a possible link? JAMA 269: 869.
13. Amsden GW, Georgian F (1996) Orthostatic hypotension induced by sertraline withdrawal. Pharmacotherapy 16: 684-686.
14. Amsterdam JD, Hornig-Rohan M, Maislin G (1994) Efficacy of alprazolam in reducing fluoxetine-induced differences in patients with major depression. J Clin Psychiatry 55: 394-400.
15. Amsterdam JD, Garcia-Espana F, Goodman D, Hooper M, Hornig-Rohan M (1998) Breast enlargement during chronic antidepressant therapy. J Affect Disord 46: 151-156.
16. Ansseau M, Gabriels A, Loyens J, et al. (1993) A double blind comparison of paroxetine and fluvoxamine in major depression. Eur Neuropsychopharmacol 3: 323-324.
17. Armitage R, Yonkers K, Cole D, Rush J (1997) A multicenter, double blind comparison of the effect of refazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 17: 161-168.
18. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR (1997) Anti-psychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 170: 23-26.
19. Arthur H, Dahl ML, Siwers B, Sjoqvist F (1995) Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 15: 211-216.
20. Arya DK (1996) Withdrawal after discontinuation of paroxetine. Aus NZJ Psychiatry 30: 702
21. Askinazi C (1996) SSRI treatment of depression with comorbid cardiac disease. Am J Psychiatry 153:135-136
22. Bacher NM, Ruskin P (1991) Addition of fluoxetine to treatment of schizophrenic patients [letter]. Am J Psychiatry 148: 274-275.
23. 3 antagonist ondansetron reduces gastrointestinal side-effects induced by a specific serotonin re-uptake inhibitor in man. J Psychopharmacol 9: 137-141.
24. Baldwin D, Fineberg N, Montgomery S (1991) Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 6: 51-58.
25. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP (1998) Double-blind, fixed dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155: 36-42.
26. Balogh S, Hendricks B (1993) Titration of serotonin reuptake blockers. J Clin Psychiatry 54: 115.
27. Banderleben UV Steiger A, Gerken A, et al. (1989) Effects of fluoxetine upon pharmacoednocrine and sleep EEG parameters in normal controls. Int Clin Psychopharmacol 4: 1-5.
28. Bangs ME, Petti TA, Janus M-D (1994) Fluoxetine-induced memory impairment in an adolescent. J Am Acad Child Adolesc Psychiatry 33: 1303-1306.
29. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG (1989) Evaluation of the potential for interactions of paroxetine with ciazepam, cimetidine, warfarin and digoxin. Acta Psychiatr Scasd 80 (Suppl. 350): 102-106.
30. Barr LC, Goodman WK, Price LH (1994) Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry 151: 289.
31. Bauer M, Linden M, Schaaf B, Weber HJ (1996) Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. J Clin Psychopharmacol 16: 130-134.
32. Beasley CM, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL (1993) Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 13: 312-320.
33. Beer K, Albertini J, Medenica M, Busbey S (1994) Fluoxetineinduced hypersensitivity. Arch Dermatol 130: 803-804.
34. Benazzi F (1996) Fluoxetine withdrawal symptoms. J Clin Psychiatry 57: 93-94.
35. Benfield P, Ward A (1986) Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 32: 313-334.
36. Bennie EH, Mullin JM, Martindale JJ (1995) A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 56: 229-237.
37. Bergeron R, Blier P (1994) Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 151: 1084-1086
38. Berlin CS (1996) Fluoxetine withdrawal symptoms. J Clin Psychiatry 57: 93-94.
39. Berti C, Ward RA, Byfield R, Henry JA (1995) Evaluation of sertraline overdoses reported in the UK. Postgraduate Med J 71: 57.
40. Bertschy G, Baumarua P, Eap CB, Baettig D (1994) Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 16: 42-45.
41. Bhatara VS, Bandettini F (1993) Serotonin syndrome and drug interactions. Clin Pharmacol Ther 1: 84-88.
42. BhataraV (1994) Venlafaxine fluoxetine interaction? Curr Affective Illness 13: 14.
43. Bigger JT Jr, Hoover CA, Steinman RC, Rolnitzky LM, Fleiss JL (1990) Autonomie nervous system activity during myocardial ischemia in man estimated by power spectral analysis of heart period variability. The Multicenter Study of Silent Myocardial Ischemia Investigators. Am J Cardiol 66: 497-498.
44. Birmaher B, Waterman GS, Ryan N, Cully M, Balach L, Ingram J, Brodsky M (1994) Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 33: 993-999.
45. Bisserbe JC, Lane R, Wiseman R (1996) Predictors of response to SSRIs in patients with major depression. Eur Neuropsychopharmacol 6 (Suppl. 3): 122.
46. Black DW, Wesner R, Gabel J (1993) The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 54: 146-149.
47. Blomgren SL, Tollefson GD (1995) Fluoxetine. N Engl J Med 332: 960.
48. Boeck V, Jorgensen A, Overø KF (1984) Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram relation to drug plasma levels. Psychopharmacology 82: 275-281.
49. Bolden-Watson C, Richelson E (1993) Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52: 1023-1029.
50. Bonin B, Bertschy G, Baumarm P, Francois T, Vandel P, Vandel S, Sechter D, Bizouard P (1996) Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration. Encephale 22: 221-227.
51. Bouchard RH, Pourcher E, Vincent P (1989) Fluoxetine and extrapyramidal side-effects. Am J Psychiatry 146: 1352-1353.
52. Bouwer CD, Harvey BH (1996) Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol 11: 273-278.
53. Boyer P, Danion JM, Bisserbe J-C, Hotton JM, Troy S (1998) Clinical and economic comparison of sertraline and fluoxetine in depression: A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 13: 157-169.
54. Boyer WF, Feighner JP (1991) Phannacokinetics and drug interactions. In Feighner JP, Boyer WF (eds), Perspectives in psychiatry, vol. 1. Selective serotonin reuptake inhibitors. John Wiley & Sons, Chichester, pp. 81-88.
55. Boyer WF, McFadden GA, Feighner JP (1991) Clinical use of the selective serotonin reuptake inhibitors. In Feighner JP, Boyer W F (eds), Perspectives in psychiatry, vol. 1. Selective serotonin reuptake inhibitors. John Wiley & Sons, Chichester, pp. 153-160.
56. Bradford J (1995) An open pilot study of sertraline in the treatment of outpatients with pedophilia. Poster presented at the 148th Annual Meeting of the American Psychiatric Association, Miami, Florida.
57. Bradley SJ, Kulik L (1993) Fluoxetine and memory impairment. J Am Acad Child Adolesc Psychiatry 32: 1078-1079.
58. Brodaty H, Peters K, Boyce P, Hickie I, Parker G, Mitchell P, Wilhelm K (1991) Age and depression. J Affect Disord 23: 137-149.
59. Brøsen K (1990) Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Phannacokinet 18: 220-239.
60. Brown WA, Harrison W (1995) Are patients who are intolerant to one SSRI intolerant to another? J Clin Psychiatry 56: 30-34.
61. Brymer C, Winograd CH (1992) Fluoxetine in elderly patients: is there cause for concern? J Am Geriatr Soc 40: 902-905.
62. Bryois C, Ferrero F (1994) Mania induced by citalopram. Arch Gen Psychiatry 51: 664-665.
63. Bryois C, Rubin Ch, Zbinden J-D, Baumann P (1998) Syndrome de sevrage aux. inhibiteurs selectifs de la serotonine: a propos d'un cas. Praxis 87: 345-348.
64. Buff DD, Brenner R, Kirtane SS, Gilboa R (1991) Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 52: 174-176.
65. Bunney WE (1978) Psychopharmacology of the switch process in affective illness. In Lipton MA, DiMascio A, Kellam KF (eds), Psychopharmacology: a generation of progress. Raven Press, New York. pp. 1249-1259.
66. Burgh van der M (1994) Citalopram product monograph. J Lundbeck, Copenhagen.
67. Burrai C, Bocchetta A, del Zompo M (1991) Mania and fluvoxamine. Am J Psychiatry 148: 1263-1264.
68. Cain JW (1992) Poor response to fluoxetine: underlying depression, serotonergic overstimulation or a 'therapeutic window'? J Clin Psychiatry 53: 272-277.
69. Caley CF, Friedman JH (1992) Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 53: 278-282.
70. Caracci G (1994) Unsuccessful suicide attemmpt by sertraline overdose. Am J Psychiatry 151:147.
71. Choo V (1993) Paroxetine and extrapyramidal reactions [letter]. Lancet 341: 624.
72. Chouinard G, Steiner W (1986) A case of mania induced by highdose fluoxetine treatment [letter]. Am J Psychiatry 143: 686.
73. Chouinard G, Sultan S (1992) A case of Parkinson's disease exacerbated by fluoxetine. Hum Psychopharmacol 7: 63-66.
74. Christensen RC (1995) Paroxetine-induced psychotic mania [letter]. Am J Psychiatry 152: 1399-1400.
75. Ciraulo DA, Shader RI (1990) Fluoxetine drug-drug interactions. Antidepressants and antipsychotics. J Clin Psychopharmacol 10: 48-50.
76. Coffey AK, Coffey DJ, Jenkyn LR, Wells BB (1994) Sertraline vs. amitriptyline vs. placebo: effects on cognitive and motor functioning in the elderly: Neuropsychopharmacology 10 (Suppl. 3): 222S.
77. Committee on Safety of Medicines (1993) Dystonia and withdrawal symptoms with paroxetine (Seroxat). Curr Prob 19: 1.
78. Cooper GL (1988) The safety of fluoxetine - an update. Br J Psychiatry 3: 77-86.
79. Coulter DM, Pillans PI (1995) Fluoxetine and extrapyramidal sideeffects. Am J Psychiatry 152: 122-125.
80. Coupland NJ, Wilson SJ, Bailey JE, Potokar J, Nutt DJ (1994) A comparison of the effects of sertraline and clomipramine on postural blood pressure changes and heart rate and blood pressure variability. Eur J Neuropsychopharmacol 4: 294-295.
81. Coupland J, Bell CJ, Potokar JP (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16: 356-362.
82. Coupland N, Wilson S, Nutt D (1997) Antidepressant drugs and the cardiovascular system: a comparison of tricyclic and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol 11: 83-92.
83. Cowen PJ, Sargent PA (1997) Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 11: 345-348.
84. Crenshaw TL, Goldberg JP (eds) (1996) Sexual pharmacology: drugs that affect sexual functioning. WW Norton & Company, New York.
85. Curran HV, Lader M (1986) The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects. Eur J Clin Pharmacol 23: 601-607
86. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, Shoaf S, Egam M, Elkashef, Liboff S, Linnoila M (1994) Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 14: 340-343.
87. Darga LL, Carroll Michals L, Botsford SJ, Lucas CP (1991) Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 54: 321-325.
88. Davis R, Wilde MI (1996) Sertraline. A pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 10: 409-431.
89. DeWilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S (1993) A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 87: 141-145.
90. Debattista C, Schatzberg AF (1995) Physical symptoms associated with paroxetine withdrawal [letter]. Am J Psychiatry 152: 1235.
91. Deijen JB, Loriaux SM, Orlebeke JF, de Vries J (1989) Effects of paroxetine and maprotiline on mood, perceptual-motor skills and eye movements in healthy volunteers. J Psychopharmacol 3: 149-155
92. Dilsaver SC, Greden JF (1984) Antidepressant withdrawal phenomena. Biological Psychiatry 19: 237-256.
93. Dominguez RA, Goodnick PJ (1995) Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 15: 778-780.
94. Donoghue JM, Tylee A (1996) The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 68: 164-168.
95. Doogan DP (1991) Toleration and safety of sertraline: Experience worldwide. Int Clin Psychoparmacol 6: 47-56.
96. Doogan DP, Caillard V (1992) Sertraline in the treatment of depression. Br J Psychiatry 160: 217-222.
97. Dorsey CM, Lukas SE, Cunningham SL (1996) Fluoxetine-induced sleep disturbance in depressed patients. Neuropsychopharmacology 14: 437-442.
98. Drake WM, Gordon GD (1994) Heart block in a patient on propanolol and fluoxetine. Lancet 343: 425-426.
99. Einbinder E (1995) Fluoxetine withdrawal? [letter]. Am J Psychiatry 152: 1253.
100. Ellison JM, Milofsky JE, Ely E (1990) Fluoxetine induced bradycardia and syncope in two patients. J Clin Psychiatry 51: 385-386.
101. Ereshefsky L (1996) Drug - drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 16 (Suppl. 2): 37S-53S.
102. Ekselius L, von Knorring L, Eberhard G (1997) A double-blind multicentre trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 12: 323-331.
103. Fahre LF, Abuzzahab FS, Amin M, Claghorn J L, Mendels J, Petrie WM, Dube S, Small JG (1995) Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 38: 592-602.
104. Fava M (1997) Anger outbursts in unipolar depressive disorders. Encephale 23: 39-42.
105. Food and Drug Administration (1993) Summary basis of approval for Paxil (paroxetine). Food and Drug Administration Freedom of Information Department, Rockville.
106. Feder R (1991) Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. J Clin Psychiatry 52: 163.
107. Fehr HF (1993) Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. Scand J Gastroenterology 28 (Suppl. 195): 40-46.
108. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS (1996) Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57: 53-62.
109. Ferguson J, Khan A, Kucharik R, Leventer S, Cucci C (1994) A placebo-controlled comparative study of the effects on blood pressure and antidepressant efficacy of venlafaxine and imipramine. Neuropsychopharmacology 10: 165S.
110. Ferguson JM, Shrivastava RK, Stahl SM, Hartford JJ, Nape B, Borian F (1996) Effects of double-blind treatment with nefazodone or sertraline on re-emergence of sexual dysfunction in depressed patients. New Research Program Abstracts American Psychiatric Association Annual Meeting, New York, p. 164.
111. Ferrier N, Silverstone T, Eccleston D (1992) Selective serotonin reuptake inhibitors: use in depression. Psychiatr Bull 16: 737-739.
112. Fineberg N, Drummond LM (1995) Anxiety disorders: drug treatment or behavioral cognitive psycotherapy? CNS Drugs 3: 448-466.
113. Finkel SI (1996) Antidepressant therapy in the old-old. J Clin Psychiatry 57 (Suppl. 5): 23-28.
114. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J (1996) Paroxetine is a novel nitric oxide synthetase inhibitor. Psychopharmacol Bull 32:653-658
115. Fitzgerald K, Healy D (1995) Dystonias and dyskinesias of the jaw associated with the use of the SSRIs. Hum Psychopharmacol 10: 215-219.
116. Fleishaker JC, Hulst LK (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Pharmacol 46: 35-39.
117. Fluoxetine Bulimia Nervosa Collaborating Study Group (1992) Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 49: 139-147.
118. Fogelson DL (1991) Obsessive-compulsive disorder, West J Med 155: 522.
119. Frank E, Kupfer DJ, Bulit CM, Levenson JA (1993) Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord 27: 139-145.
120. Frasure-Smith N, Lesperance F, Talajic M (1993) Depression following myocardial infarction. Impact on 6-month survival. JAMA 270: 1860-1861.
121. Frost L, Lal S (1995) Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors [letter]. Am J Psychiatry 152: 810.
122. Gagiano CA (1993) A double-blind study to compare paroxetine and fluoxetine in patients with major depression. Br J Clin Res 4: 145-152.
123. Gardner MJ, Baris BA, Wilner KD, Preskorn SH (1997) Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 32 (Suppl. 1): 43-19.
124. Geretsegger C, Bohmer F, Ludwig M (1994) Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 9: 25-29.
125. Ghaziuddin M (1994) Mania induced by sertraline in prepubertal child. Am J Psychiatry 151: 944.
126. Gillin JC, Rapaport M, Erman MK, et al. (1997) Comparative effects of nefazodone and fluoxetine on mood, and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 58: 185-192.
127. Gillman K (1997) Serotonin syndrome -clomipramine too soon after moclobemide? Int Clin Psychopharmacol 12: 339-342.
128. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RJ (1991) Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 148: 790-792.
129. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E (1995) A placebo-controlled trial of fluoxetine added to neuroleptic inpatients with schizophrenia. Psychopharmacology 117: 417-423.
130. Goldstern DJ, Wilson MG, Thompson VL, Potvin JH, Rampey AH Jr (1995) Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br J Psychiatry 166: 660-666.
131. Gordon C, Whale R, Cowen PJ (1998) Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology 137: 201-202.
132. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF (1987) An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 7: 329-339.
133. Gram LK Guentert TW, Grange S, Vistisen K, Brosen K (1995) Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 57: 670-677.
134. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard B, Rasmussen S, White K, Sikes C (1995) Double-blind parallel comparison of three dosages of sertraline in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatr 52: 289-295
135. Gregor KJ, Riley JA, Downing DK (1996) Concomitant use of anxiolytics and hypnotics with selective serotonin reuptake inhibitors. Clin Ther 18: 521-527.
136. Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F, Eklundh G (1997) Symptoms and signs of severe citalopram overdose. Lancet 349: 1602.
137. Hamilton MS, Opler LA (1992) Akathisia, suicidality and fluoxetine. J Clin Psychiatry 53: 401-406.
138. Harto NE, Spera KF, Branconnier RJ (1988) Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacol Bull 24: 220-223.
139. Harvey AT, Burke M (1995) Serotonin syndrome associated with paroxetine, an over-the-counter cold remedy and vascular disease. Am J Emerg Med 13: 605-607.
140. Hauser RA, Zesiewicz TA (1997) Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 12: 756-759.
141. Heimann SW, March JS (1996) SSRI-induced mania. J Am Acad Child Adolesc Psychiatry 35: 4.
142. Hendrickse WA, Roffwarg HP, Grannemann BD, Orsulak PJ, Armitage R, et al. (1994) The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study. Neuropsychopharmacology 10: 85-91.
143. Henry JA, Antao CA (1992) Suicide and fatal antidepressant poisoning. Eur J Med 1: 343-348.
144. Herberg KW, Menke H (1981) Study of the effects of the antidepressant fluvoxamine on driving skills and its interaction with alcohol [technical report], TÜV, Rheinland Köln.
145. Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF (1990) Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 51: 25-27.
146. Hindmarch I, Bhatti J (1988) Psychopharmalogical effects of sertraline in normal healthy volunteers, Eur J Clin Pharmacol 35: 221-223.
147. Hindmarch I, Harrison C (1988) The effects of paroxetine and other antidepressants in combination with alcohol on psychomotor activity related to car driving. Hum Psychopharmacol 3: 13-20.
148. Hindmarch I, Shillingford J, Shillingford C (1990) The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 51 (Suppl. 12B): 34-36.
149. Hoehn-Saric R, Lipsey JR, McLeod DR (1990) Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 10: 343-345.
150. Hoehn-Saric R, Harris GJ, Pearlson GD, Cox CS, Machlin SR, Camargo EE (1991) A fluoxetine-induced frontal lobe syndrome in an obsessive-compulsive patient. J Clin Psychiatry 52: 131-133.
151. Hon D, Preskorn SH (1989) Mania during fluoxetine treatment for recurrent depression. Am J Psychiatry 146: 1638-1639.
152. Horrigan JP, Barnhill LJ (1994) Paroxetine-pimozide drug interaction. J Am Acad Child Adolesc Psychiatry 33: 1060-1061.
153. Hussein S, Kaufman BM (1994) Bradycardia associated with fluoxetine in an elderly patient with sick sinus syndrome. Postgrad Med J 70: 56.
154. HylanTR, Neslusan CA, Baldridge RM, Meneades L, Crown WH, et al. (1997) SSRI antidepressant selection and anxiolytic and sedative-hypnotic use. J Clin Outcome Management 4: 16-22.
155. Hyttel J (1993) Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nord J Psychiatry 47 (Suppl. 30): 5-20.
156. Jacobs BL, Azmitia EC (1992) Structure and function of the brain serotonin system. Physiol Rev 72: 165-229.
157. Jacobsen FM (1992) Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 53: 119-122.
158. Johnson DAW (1981) Depression: treatment compliance in general practice. Acta Psychiatr Scand 63 (Suppl. 290): 447-453.
159. Jordan J, Messerli FH, Lavie CJ, Aepfelbacher FC, Soria F (1995) Reduction of weight and left ventricular mass with serotonin uptake inhibition in obese patients with systemic hypertension. Am J Cardiol 75: 743-744
160. Joubert AF, Gagiano CA, Joubert G (1996) Antidepressants and weight: comparative study of four antidepressants and their effect on weight. Eur Neuropsychopharmaeol 6 (Suppl. 3): 143.
161. Kaminski CA, Robbins MS, Weibley RE (1994) Sertraline intoxication in a child. Ann Emerg Med 23: 1371-1374.
162. Kasantikul D (1995) Reversible delirium after discontinuation of fluoxetine. J Med Assoc Thailand 78: 53-54.
163. Kassner J, Wolf A (1992) Sertraline HCl: a new antidepressant. Vet Hum Toxicol 34: 343.
164. Kat H (1996) More on SSRI-induced mania. J Am Acad Child Adolesc Psychiatry 35: 975.
165. Katon W, von Korff M, Lin E, Bush T, Ormel J (1992) Adequacy and duration of antidepressant treatment in primary care. Med Care 30: 67-76.
166. Katzelnick DJ, Kobak KA, Jefferson JW, et al. (1996) Prescribing patterns of antidepressant medications for depression in an HMO. Formulary 31: 374-388.
167. Kavoussi RJ, Liu J, Coccaro E (1994) An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 55: 137-141.
168. Keck PE, Hudson JI. Dorsey CM, et al. (1991) Effect of fluoxetine on sleep [letter]. Biol Psychiatry 29: 618-619.
169. Keck PE, McElroy SL (1992) Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. J Clin Psychiatry 53: 127-129.
170. Kelsey MC, Grossberg GT (1994) Sertraline and weight change in elderly depressed patients-a retrospective study. Am J Geriatr Psychiatry 2: 271.
171. Kerkhofs M, Rielaerat C, De Maertelaer V, et al. (1990) Fluoxetine in major depression: efficacy, safety, and effects on sleep polygraphic variables. Int Clin Psychopharmacol 5: 253-260.
172. Kerr JS, Sherwood N, Hindmarch I (1991) The comparative psychopharmacology of 5-HT reuptake inhibitors. Hum Psychopharmacol 6: 313-317.
173. Kerr JS, Fairweather DB, Mahendren R, Hindmarch I (1992) The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. Int Clin Psychopharmacol 7: 101-108.
174. Ketai R (1993) Interaction between fluoxetine and neuroleptics. Am J Psychiatry 150: 836-837.
175. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA (1994) Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 14. 206-207.
176. Kiev A, Feiger A (1997) A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58: 146-152.
177. Klein-Sehwartz W, Anderson B (1996) Analysis of sertraline only overdoses- Am J Emerg Med 14: 456-458.
178. Kline MD (1989) Fluoxetine and anorgasmia. Am J Psychiatry 146: 804-805.
179. Ko S-M (1995) Pharmacotherapy of obsessive-compulsive disorder. Br J Clin Pract 49: 36-39.
180. Kroboth PD, Folan MM, Lush RM, Chaikm PC, Shukla UA, Barbhaiya R, Salazar D E (1995) Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. J Clin Psychopharmacol 15: 306-319.
181. Kroboth PD, Bonate PL, Smith RB, Suarez E, Oo C (1997) Clonazepam (Klonopin) and sertraline (Zoloft): absence of drug interaction in a multiple dose study. Clin Pharmacol Therap 61: 178.
182. Lader M, Melhuish A, Freka G, Fredricson Overo K, Christensen V (1986) The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol 31: 183-190.
183. Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Maki-Ikola O, Reinikainen K, Scheinin M (1997) Lack of adverse interactions between concomitantly administered selegeline and citalopram. Clin Neuropharmacol 20: 419-433.
184. Landry P, Roy L (1997) Withdrawal hypomania associated with paroxetine. J Clin Psychopharmacol 17: 60-61.
185. Lane R (1996a) Pharmacokinetic drug interaction potential of serotonin reuptake inhibitors. International Clin Psychopharmacol 11 (Suppl. 5): 31-61.
186. Lane R (1996b) Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs). J Serotonin Res 3: 75-83.
187. Lane R, Baldwin D (1997) Selective serotonin reuptake inhibitorinduced serotonin syndrome. J Clin Psychopharmacol 17: 208-221.
188. Lane RM (1997) A critical review of SSRI-related sexual dysfunction, incidence, possible aetiology and implications for management. J Psychopharmacol 11: 72-82.
189. Lane RM (1998) SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 12: 208-230.
190. Lane R, Fischler B (1995) The serotonin syndrome: coadministration, discontinuation and washout periods for the selective serotonin reuptake inhibitors (SSRIs). J Serotonin Res 3: 171-180.
191. Lane R, Sweeney M, Henry JA (1994) Pharmacotherapy of the depressed patient with cardiovascular and/or cerebrovascular illness. Br J Clin Pract 48: 256-262.
192. Lantz MS, Buchalter EN, Giambanco V (1995) Side effects of antidepressants in very old nursing home residents. New Research Program and Abstracts. Paper presented at the 148th Annual Meeting of the American Psychiatric Association, Miami.
193. Laporta M, Chouinard G, Goldbloom D, Beauclair L (1987) Hypomania induced by sertraline, a new serotonin reuptake inhibitor. Am J Psychiatry 144: 1513-1514.
194. Lasher TA, Fleishaker JC, Steenwyck RC, Antal EJ (1991) Pharmacokinetic, pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 104: 323-327.
195. Latimer PR, Ravindran AV Bernatchez J-P, Fournier J-P, Gojer JA, Barrat K, Buttars J (1996) A six month comparison of toleration and efficacy of sertraline and fluoxetine treatment of major depression. Eur Neuropsychopharmacol 6 (Suppl. 3): 124
196. Lau GT, Horowitz BZ (1996) Sertraline overdose. Acad Emerg Med 3: 132-136.
197. Lavin M R, Mendelowitz A, Block SH (1993) Adverse reaction to high-dose fluoxetine [letter]. J Clin Psychopharmacol 13: 452-453.
198. Layton M E, Dager S R (1994) Optimum treatment of panic disorder. CNS Drugs 2: 208-215.
199. Lebegue ME (1987) Mania precipitated by fluoxetine. Am J Psychiatry 144: 16-20.
200. Lejoyeux M, Ades J, Rouillon F (1994) Serotonin syndrome: incidence, symptoms and treatment. CNS Drugs 2: 132-143.
201. Leonard BE (1993) The comparative pharmacology of new antidepressants. J Clin Psychiatry 54 (Suppl. 8): 3-15.
202. Leyman S, Mattlaer PM, Van Steenberge I, Schotte G (1995) Paroxetine: postmarketing experience on 4024 depressed patients in Belgium. Eur J Clin Res 7: 287-296.
203. Linden RD, Newhouse P, Krishnan KR, et al. (1995) SSRIs in the depressed elderly: A double-blind comparison of sertraline and fluoxetine in depressed geriatric out-patients. Poster presented at the 148th Annual Meeting of the American Psychiatric Association. Miami.
204. Linnoila M (1993) Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. J Clin Psychopharmacol 13: 175-180.
205. Lipinski JF Jr, Mallya G, Zimmerman P, Pope HG Jr (1989) Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 50: 339-342.
206. Llerena A, Aim C, Dahl ML, Equist B, Bertilsson L (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14: 92-97.
207. Lock JD, Gwirtsman HE, Targ EF (1990) Possible adverse drug interactions between fluoxetine and other psychotropics. J Clin Psychopharmacol 10: 383-384.
208. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C (1998) Sertraline in the treatment of panic disorder: a multisite, double-blind, placebocontrolled fixed dose investigation. Br J Psychiatry (in press).
209. Louwerens JW, Gloerich ABM, de Vries G, Brookhuis KA, O'Hanlon JF (1987) The relationship between driver's blood alcohol concentration (BAC) and actual driving performance during high speed travel. In Noordzij PC, Roszbach R (eds), Alcohol, drugs and traffic safety-T86. Excerpta Medica, Amsterdam, pp. 183-186.
210. Lydiard RB, George MS (1989) Fluoxetine-related anorgasmy. South African Med J 82: 933-934.
211. MaeDonald TM, McMahon AD, Reid IC, Fenton GW, McDevitt DG (1996) Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. Br Med J 313: 860-861.
212. Mackay F, Dunn N, Wilton L, Pearce GL, Freemantle SN, Mann RD (1997) A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Safety 6: 235-236.
213. Malek-Almadi P, Allen SA (1995) Paroxetine-molindone interaction. J Clin Psychiatry 56: 82-83.
214. Mallya G, White K, Gunderson C (1993) Is there a serotonergic withdrawal syndrome? Biol Psychiatry 33: 851-852.
215. Malt UF, Robak OH, Madsbu H-P, Bakke O, Loeb M, Smedsrud T (1995) Practical aspects of long-term treatment. Eur Neuropsychopharmacol 5: 288-289.
216. Marchiando RJ, Cook MD (1995) Probable terfenadine-fluoxetine associated cardiac toxicity. Ann Pharmacother 29: 937-938.
217. Marchioni E, Perucca E, Soragna D, BO P, Malaspina A, Ferrandi D, Albergati A, Savoldi F (1996) Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. Neurology 46: 853.
218. Markovitz JH, Mathews KA, Kiss J, Smitherman TC (1996) Effects of hostility on platelet reactivity to psychological stress in coronary heart disease patients and in healthy controls. Psychosomatic Med 58: 143-149.
219. Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR (1995) Adverse events in PTSD patients taking fluoxetine [letter]. Am J Psychiatry 152: 1238-1239.
220. Mattila MJ, Saarialho-Kere U, Mattila M (1988) Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age. J Clin Psychiatry 49 (Suppl. 8): 52-58.
221. McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM Jr, Gross LS (1990) The cost of antidepressant drug failure: a study of antidepressant use patterns in the Medicaid population. J Clin Psychiatry 51 (SuppL): 60-69.
222. McElroy SL, Keck PE, Friedman LM (1995) Minimizing and managing antidepressant side-effects. J Clin Psychiatry 56 (Suppl. 2): 49-55.
223. McEntee WJ, Crook TH (1991) Serotonin, memory, and the aging brain. Psychopharmacology 103: 143-149.
224. McEntee W, Ko G, Richter E (1996) Sertraline and nortriptyline: heart rate, cognitive improvement and quality of life in depressed elderly. Eur Neuropsychopharmacol 6 (Suppl. 3): 36.
225. McGrath PJ, Quitkin FM, Klein DF (1995) Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. J Clin Psychopharmacol 15: 289-291.
226. Meara RJ, Bhowmick BK, Hobson JP (1995) Treatment of depression in Parkinson's disease using sertraline. Poster presented at the BAP/BNPA Summer Meeting, Cambridge, UK.
227. Medical Economics Data (1997a) Prozac (fluoxetine hydrochloride). Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 943-947.
228. Medical Economics Data (1997b) Paxil (paroxetine hydrochloride) Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 2681-2686.
229. Medical Economics Data (1997c) Zoloft (sertraline hydrochloride). Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 2051-2053.
230. Medical Economics Data (1997d) Effexor (venlafaxine hydrochloride). Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 2825-2829.
231. Medical Economics Data (1997e) Luvox (fluvoxamine maleate). Physicians desk reference (51st edn). Medical Economics Data Production Co., Montvale, NJ, pp. 2723-2726.
232. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC (1979) Extrapyramidal side-effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transmission 45; 165-175.
233. Michael A, Herrod JJ (1997) Citalopram-induced decreased libido [letter]. Br J Psychiatry 171: 90.
234. Michelson D, Reimherr FW, Beasley CM, Wilson M (1997) Optimal length of continuation therapy: a prospective assessment during fluoxetine long term treatment of MDD. New Research Program and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego.
235. Miller LG, Bowman RC, Mann D, Tripathy A (1989) A case of fluoxetine-induced serum sickness. Am J Psychiatry 146: 1616-1617.
236. Mills KC (1995) Serotonin syndrome. Am Fam Physician 52: 1475-1482.
237. Minnery KL, West SA, McConville BJ, Sorter MT (1995) Sertraline-induced mania in an adolescent [letter]. J Child Adol Psychopharmacol 5: 151-153.
238. Mirow S (1991) Cognitive dysfunction associated with fluoxetine. Am J Psychiatry 148: 948-949.
239. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Caleedo A, Carrasco JL, Ciudad J, Daniel E, De La Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin T, Perez V, Sanchez JM, Sanchez JM, Vicens E (1997) SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Therapy 23: 176-194.
240. Montgomery SA, Henry JA, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D (1994) Selective serotonin reuptake inhibitors - meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47-53.
241. Mortimore C, Blacker CVR (1996) A naturalistic prospective study of the use of fluoxetine in general psychiatric outpatients. Hum Psychopharmacol 11: 365-372.
242. Moscovitch A, Wiseman L, Goldberg MS, Lane RM (1995) A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. New Research Programs and Abstracts. Paper presented at the 148th Annual Meeting of the American Psychiatric Association, Miami.
243. Mulholland C, Lynch G, Cooper SJ, King DJ (1997) A double-blind, placebo-controlled trial of sertraline for depressive symptoms in stable, chronic schizophrenia. Biol Psychiatry 42: 188S.
244. Myers LB, Dean BS, Krenzelok EP (1993) Sertraline (Zoloft): overdose assessment of a new antidepressant. Vet Hum Toxicol 35: 341.
245. Nakra BRS, Szwabo P, Grossberg GT (1989) Mania induced by fluoxetine. Am J Psychiatry 146: 1515-1516.
246. Naranjo CA, Sellers EM, Sullivan JT, et al. (1987) The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Therap 41: 266-274.
247. Nedergaard S, Bolam JP, Greenfield SA (1988) Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature 333: 174-177.
248. Nemeroff CB, Ninan PT, Ballenger JC, Lydiard RB, Feighner J, Patterson WM, Greist JH (1995) Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression 3: 163-169.
249. Newhouse PA, Ko G, Richter EM (1996) Comparison of sertraline and fluoxetine in depressed geriatric outpatients: plasma levels and efficacy. Eur Neuropsychopharmacol 6 (Suppl. 3): 35.
250. Nicholson A N, Pascoe PA (1988) Studies on the modulation of the sleepwakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor, Neuropsychopharmacology 27: 597602.
251. Niznik HB, Tyndale RF, Sallee RF, Gonzalez FJ, Hardwick JP, Inaba T, Kalow W (1990) The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain; resolution and identification of two distinct (3H) GBR-12935 binding proteins. Arch Biochem Biophys 276: 424-432.
252. Nyth AL, Gottfries CG (1990) The clinical efficacy of citalopram in the treatment of emotional disturbances in dementia disorders. A nordic multicenter study. Br J Psychiatry 157: 894-901.
253. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM (1995) Paroxetine in the treatment of panic disorder. A randomized double-blind, placebo-controlled study. Br J Psychiatry 167: 374-379.
254. O'Hanlon JF, Robbe HWJ, Vermeeren A, van Leeuwen C, Danjou PE (1998) Venlafaxine effects on healthy volunteers during 15-day fixed (75 mg/day) and incremental (75-150 mg/day) dosing regimens. J Clin Psychopharmacol 18: 212-221.
255. Öström M, Eriksson A, Thorson J, Spigset O (1996) Fatal overdose with citalopram. Lancet 348: 339-340.
256. Oswald I, Adams K (1986) Effects of paroxetine on human sleep. Br J Clin Pharmacol 22: 97-99.
257. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Therap 283: 1305-1322.
258. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Kalow W (1998) Paroxetine potentiates CNS side-effects of perphenzine: contribution of cytochrome P450 2D6 inhibition in vivo. Clin Pharmacol Ther 62: 334-347.
259. Pacheco L, Malo P, Aragues E, Etxebeste M (1996) More cases of paroxetine withdrawal syndrome. Br J Psychiatry 169: 384.
260. 2c receptor. Psychopharmacology 126: 234-240.
261. Patris M, Bouchard J-M, Bougeral T, Charbonnier J-F, Chevalier J-F, Clerc G. Cyran C, Van-Amerongen P, Lemming O, Hopfner Petersen HE (1996) Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trials in patients with unipolar depression treated in general practice. Int Clin Psychopharmacol 11: 129-136.
262. Pedersen L, Klysner R (1997) Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazepine. Int Clin Psychopharmacol 12: 59-60.
263. Peet M (1994) Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. BrJ Psychiatry 164: 549-550.
264. Personne M, Sjoberg G, Persson H (1997) Citalopram overdosereview of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 35: 237-240.
265. Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Saback S, Gips M, Bialer M (1994) Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacot Ther 54: 471-476.
266. Peyre F, Verdoux H, Bourgeois M (1992) Fluvoxamine. Study of the relation between posology and plasma levels in a group of 80 hospitalized patients with depression. Encephale 18: 76-78,
267. Phillips SD (1995) A possible paroxetine withdrawal syndrome [letter]. Am J Psychiatry 152: 645-646.
268. Piazza LA, Markowitz J, Kocsis J, Leon A, Miller N, Adler D (1997) Gender differences in sexual functioning of chronically depressed patients treated with SSRI antidepressants: a pilot study. Poster presented at 37th Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton.
269. Pollock BG, Mulsant BH, Sweet RA, Rosen J, Altieri LP, Perel JM (1995) Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 31: 327-331.
270. Preskorn SH (1995) Clinical pharmacology of selective serotonin reuptake inhibitors. Professional Communications, Inc. Caddo.
271. Preskorn SH, Lane RM (1995) Sertraline 50 mg daily - the optimal daily dose in depression. Int Clin Psychopharmacol 10: 129-141.
272. Preskorn SH, Janicak PG, Davis JM, Ayd F Jr (1995) Advances in the pharmacotherapy of depressive disorders. In Janicak PG, Davis JM, Preskorn SH, Ayd FJ (eds), Principals and practice of psychopharmacotherapy. Williams & Wilkins, Baltimore, pp. 1-24.
273. Preskorn SH, Alderman JA, Greenblatt DJ, Horst DW (1997) Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 33: 659-665.
274. Preskorn SH, Shad M, Alderman J, Lane R (1998) Fluoxetine: age and dose dependent pharmacokinetics and CYP 2C19 inhibition [abstract]. Clin Pharmacol Therap 63: 166.
275. Price JS, Waller PC, Wood SM, MacKay AVP (1996) A comparison of the postmarketing safety of four selective serotonin reuptake inhibitors including the investigstion of symptoms occurring on withdrawal. Br J Clin Pharmacol 42: 757-763.
276. Pruder KL, Wood LL, Sherrill A (1997) Health economics with retrospective data: selection bias issues. J Int Med Res 25: 45-47.
277. Ramaekers JG, Muntjeweroff ND, O'Hanlon JF (1995) A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Psychopharmacol 39: 397-404
278. Ramaekers JG, Ansseau M, Muntjeweroff ND, Sweens JP, O'Hanlon JF (1997) Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients. Int Clin Psychopharmacol 12: 159-169.
279. Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes K (1996a) Absence of effects of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 57 (Suppl. 1): 24-28.
280. Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K (1996b) Absence of effects of sertraline mediated effects on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 57 (Suppl. 1): 20-23.
281. Rascati K (1995) Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Therapeutics 17: 786-790.
282. Reeves RR, Pinofsky HB (1996) Lhermitte's sign in paroxetine withdrawal. J Clin Psychopharmacol 16: 411-412.
283. Richelson E (1993) Treatment of acute depression. Psychiatr Clin North Am 16: 461-478.
284. Riehelson E (1994) The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 55 (Suppl. A): 34-39.
285. Richelson E (1998) Weight gain on SSRIs: A paradox? Primary Psychiatry 5: 40-41.
286. Rickels K, Schweizer E (1990) Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 51 (Suppl. 12B): 9-12.
287. Riley AJ, Riley EJ (1993) Evaluation of drug effects on human sexual dysfunction. In Riley AJ, Peet M, Wilson C (eds). Sexual pharmacology. Clarendon Press, Oxford, pp. 114-129.
288. Robbe HWJ, O'Hanlon JF (1995) Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 5: 35-42.
289. Roose SP, Glassman AH, Attia E, Woodring S (1994) Comparative efficacy of selective serotonin reuptake inhibitors in the treatment of melancholia. Am J Psychiatry 151: 1735-1739
290. Roose SP, Glassman AH, Giardina EG, Walsh BT, Woodring S, Bigger JT (1987) Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 44: 273-275.
291. Roose SP, Glassman AH, Dalack GW (1989) Depression, heart disease, and tricyclic antidepressants. J Clin Psychiatry 50 (Suppl. 7): 12-17.
292. Rosenberg DR, Johnson K, Sahl R (1992) Evolving mania in an adolescent treated with low-dose fluoxetine. J Child Adol Psychopharmacol 2: 299-306.
293. Rosenstock HA (1996) Sertraline withdrawal in two brothers: a. case report. Int Clin Psychopharmacol 11: 58-59.
294. Rothschild AJ, Locke CA (1991) Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 52: 491-493.
295. Russel JM, Finkelstein S, Greenberg P, Berndt E, Baker A, Keller M B (1997) The economic impact of the treatment of depression. New Research Program and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego.
296. Russel JM, Berndt E, Miceh R (1998) Course and cost of treatment with SSRIs. New Research Abstracts American Psychiatric Association Annual Meeting, Toronto.
297. Sachdev P (1995) The identification and management of druginduced akathisia. Drugs 4: 28-46.
298. Saletu B, Grunberger J, Linzmayer L (1986) On central effects of serotonin re-uptake inhibitors: quantitative EEG and psychometric studies with sertraline and zimelidine. J Neural Transm 67: 241-266.
299. Sclar DA, Robison LM, SkaerTL, Legg RF, Nemec NL, Galin RS, Hughes TE, Buesching DP (1994) Antidepressant pharmacotherapy: Economic outcomes in health maintenance organization. Clin Ther 16: 715-730.
300. Sclar DA, Robison LM, Skaer TL, Galin RS, Legg R F, Nemec NL, Hughes TE, Buesehing DP, Morgan M (1995) Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 23: 395-412.
301. Sechter D, Troy S (1997) Double blind randomized comparative study of sertraline and fluoxetine in depressive outpatients. Biol Psychiatry 42: 259S.
302. Segraves RT (1993) Treatment-emergent sexual dysfunction in affective disorder: a review and management strategies- J Clin Psychiatry Monograph 11: 57-60.
303. Settle EC Jr, Settle GP (1984) A case of mania associated with fluoxetine. Am J Psychiatry 141: 280-281.
304. Sewitch DE, Binianr IV, Philips JL, Winokur A (1991) Sleep architecture and mood effects of setraline in outpatients with major depression: a preliminary report. Sleep Res 20: 189.
305. Shapiro LE, Knowles SR, Shear NH (1997) Fluoxetine-induced serum sickness-like reaction. Ann Pharmacother 31: 927.
306. Sharpley AL, Cowen PJ (1995) Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 37: 85-98.
307. Sharpley AL, Williamson DJ, Attenburrow M EJ, et al. (1996) The effects of paroxetine and nefazodone on sleep: a placebocontrolled trial. Psychopharmacology 126: 50-54.
308. Shasha M, Miller SI, Lyons JS, Howard KI, O'Mahoney MT, Rosenberg A (1997) Serotonin reuptake inhibitors and the adequacy of antidepressant treatment. Int J Psychiatry Med 27: 83-92.
309. Shatzberg A F, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum J F, Young A H, Zajecka J (1997) Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition, J Clin Psychiatry 58 (Suppl. 7):5-10.
310. Shrivastava RK, Cohn C, Crowder J, Davidson J, Dunner D, Feighner J, Kiev A, Patrick R (1994) Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 14: 322-329.
311. Shulman LM, Singer C, Liefert R, Mellman T, Weiner W J (1996) Therapeutic effects of sertraline (Zoloft) in patients with Parkinson's disease. Movement Disord 11: 603.
312. Simmons J (1996) Fluoxetine in Parkinson's disease [letter]. Movement Disord 11: 581-582.
313. Simon G E, Wagner E, Von Korf M (1995) Cost-effectiveness comparisons using 'real world' randomized trials: The case of new antidepressant drugs. J Clin Epidemol 48: 363-373.
314. Simone EM (1997) Dermatologic side-effects of medication. Pharmacist 22: 60-73.
315. Singh RK, Gupta AK, Singjh B (1995) Acute organic brain syndrome after fluoxetine treatment. Am J Psychiatry 152: 295-296.
316. Singletary T, North DS, Weiss M, Marman G (1997) A cost-effective approach to the use of selective Serotonin reuptake inhibitors in a Veterans Affairs Medical Center. Am J Man Care 3: 125-129.
317. Skaer TL, Sclar DA, Robison LM, et al. (1995) Economic evaluation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res 56: 556-567.
318. Skop BP, Brown TM (1996) Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 37: 12-16.
319. Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM (1994) The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy and vascular disease. Am J Emerg Med 12: 642-644.
320. Small GW, Hamilton SH, Bystritsky A, Meyers BS, Nemeroff CB, and the Fluoxetine Collaborative Study Group (1995) Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Int Psychogeriatrics 7 (Suppl.): 41-53.
321. Søgaard JA, Verbruggen WP, Goodwin DP (1997) A double-blind efficacy and tolerability study of sertraline and moclobemide in atypical depression. Biol Psychiatry 42: 248S-249S.
322. Solyom L, Solyom C, Ledwidge B (1990) The fluoxetine treatment of low-weight, chronic bulimia nervosa. J Clin Psychopharmacol 10: 421-425.
323. Stahl MMS, Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Taylor NFA, Fletcher A P, Schou J S (1998) Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 53: 163-169.
324. Stahl SM (1998) How psychiatrists can build new therapies for impotence. J Clin Psychiatry 59: 47-48.
325. Stein M H (1991) Tardive dyskinesia in a patient taking haloperidol and fluoxetine [letter]. Am J Psychiatry 148: 683.
326. Stein M B, Chartier M J, Hazen A L. Kroft CDL, Chale R A, Cote D, Walker JR (1996) Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebocontrolled discontinuation. J Clin Psychopharmacol 16: 218-222.
327. Sternbach H (1988) Danger of MAOI therapy after fluoxetine withdrawal [letter]. Lancet 2: 850-851.
328. Sternbach H (1991) Fluoxetine associated potentiation of calcum channel blockers. J Clin Psychopharmacol 11: 390.
329. Steur EN (1993) Increase of Parkinson disability after fluoxetine medication. Neurol 43: 211-213.
330. Stoker MJ, Eric L (1993) A comparison of withdrawal effects following discontinuation of paroxetine and imipramine. New Research Program and Abstracts. Paper presented at the American Psychiatric Association 146th Annual Meeting, San Francisco.
331. Stoukides JA, Stoukides CA (1991) Extrapyramidal symptoms upon discontinuation of fluoxetine [letter]. AmJ Psychiatry 148: 1263.
332. Sussman N, Ginsberg D (1998) Weight gain associated with SSRIs. Primary Psychiatry 5: 28-37.
333. Sussman M, Stahl S (1996) Update in the pharmacotherapy of depression. Am J Med 101 (Suppl 6A): 26S-36S
334. Tanda G, Frau R, Di Chiara G (1996) Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology 127: 83-87.
335. Tate J L (1989) Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 146: 399-400.
336. Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249-258.
337. Teicher M, Glod C, Cole J (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147: 207-210.
338. Thakore JH, Berti C, DinanTG (1996) An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. Acta Psychiatr Scand 94: 194-197.
339. The Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic moricizine on survival after myocardial infarction. N Engl J Med 327: 227-233.
340. Tierney E, Joshi PT, Llinas JF, et al. (1995) Sertraline for major depression in children and adolescents: preliminary clinical experience. J Child Adolesc Psychopharmacol 5: 13-27.
341. Tignol J (1993) A double-blind randomized multicenter comparison of paroxetine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 13 (Suppl. 2): 18S-22S.
342. Tollefson GD, Rampey AH, Beasley CM, Enas GG, Potvin JH (1994) Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 14: 163-169.
343. Turner SM, Jacob RG, Beidel DC, Griffin S (1985) A second case of mania associated with fluoxetine [letter]. Am J Psychiatry 142: 274-275.
344. Tyndale R F, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB (1991) Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 40: 63-68.
345. Van Ameringen M, Mancini C (1992) Adverse effects of switching from fluoxetine to desipramine [letter]. Can J Psychiatry 37: 278.
346. van Harten J, Stevens LA, Raghoebar M, Holland RL, Wesnes K, Cournot A (1992) Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther 52: 427-435.
347. Van Moffaert M, Bartholome F, Cosyns P, De-Nayer A R, Mertens C (1995) A controlled comparison of sertraline and fluoxetine in acute and continuation therapy of major depression. Hum Psychopharmacol 10: 393-405.
348. Vandel P, Bonin B, Vandel S, Sechter D, Bizouard P (1996) CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal sideeffects. Med Hypotheses 47: 439-442.
349. Varela A L (1996) Sexual side-effects during sertraline treatment of patients with major depression: a naturalistic study. Eur Neuropsychophannacology 6: 124.
350. Venkataraman S, Naylor MW, King CA (1992) Mania associated with fluoxetine treatment in adolescents. J Am Acad Child Adol Psychiatry 31: 265-281.
351. Vincent A, Douville M, Baruch P (1991) Serum sickness induced by fluoxetine. Am J Psychiatry 148: 1602-1603.
352. Volkow N D, Gur R C, Wang G-J, Fowler JS, Moberg PJ, Ding Y-S, Hitzemann R, Smith G, Logan J (1998) Association between decline in brain dopamine activity with age and cognitive and motor impaiment in healthy individuals. Am J Psychiatry 155: 344-349.
353. Waldmger M D (1997) Treatment of primary premature ejaculation: a model for investigation of SSRI-induced sexual side-effects. New Research Program and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego.
354. Waldmger MD, Hengeveld MW, Zwinderman A H (1997) Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, doseresponse study. Br J Urol 79: 592-595.
355. Walley T, Pirmhamed M, Proudlove C, Maxwell D (1993) Interaction of metoprolol and fluoxetine. Lancet 341: 967-968.
356. Walczak DD, Apter JT, Halikas JA, Borison RL, Carman JS, Post G L, Patrick R, Cohn JB, Cunningham LA, Rittberg B, Preskorn SH, Kang JS, Wilcox CS (1996) The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 8: 139-151.
357. Wehr TA, Goodwin F K (1987) Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 144: 1403-1411.
358. Weinstein A, Wilson S, Bailey J, Nutt D (1996) Sedative antidepressats impair visual detection mechanisms in humans. J Psychopharmacol 10: 141-145.
359. Widlocher D J (1983) Psychomotor retardation: clinical, theoretical and psychometric aspects. Psychiatry Clin North Am 5: 27-29.
360. Wilcox JA (1987) Abuse of fluoxetine by a patient with anorexia nervosa. Am J Psychiatry 144: 1100.
361. Williams SA, Wesnes K, Oliver SD, Rapeport WG (1996) Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. J Clin Psychiatry 57: 7-11.
362. WingY-K, Clifford EM, Sheehan BD, Campling GM, Hockney RA, Cowen PJ (1996) Paroxetine treatment and the prolactin response to sumatriptan. Psychopharmocology 124: 377-379.
363. Winokur A, Reynolds CF III (1994) The effects of antidepressants on sleep physiology. Primary Psychiatry 11: 22-27.
364. Winokur A, Lexow N, Allen K, Reed D, Breitmeyer W (1994) Sertraline administered for 8 weeks to depressed patients did not alter sleep architecture: a preliminary report. New Research Program and Abstracts American Psychiatry Association Annual Meeting; Philadelphia.
365. Wong DTY, Threlkeld P G, Robertson D W (1991) Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology 5: 43-47.
366. Wood A (1993) Pharmacotherapy of bulimia nervosa - experience with fluoxetine. Int Clin Psychopharmacol 8: 295-299.
367. Zajecka J, Mitchell S, Fawcett J (1997) Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull 33: 755-760.
368. Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Beasley C (1998) Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 18: 193-197.
369. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E (1996) Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 153: 1631-1633.
370. Zehender M, Hohnloser S, Just H (1991) QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther 5: 515-530.
371. Zerbe RL (1987) Safety of fluoxetine in the treatment of obesity. Int J Obesity 11 (Suppl. 3): 191-199.
372. Zubenko GS, Cohen BM, Lipinski JF (1987) Antidepressantinduced akathisia. J Clin Psychopharmacol 7: 254-257.